Holmusk Expands NeuroBlu Real-World Data Platform to 46 Million Patients with Alzheimer's Biomarker and Neurological Outcomes Depth
核心洞察
Holmusk (搜索)'s NeuroBlu 26R2 release expands to over 46 million de-identified patient lives, adding more than 5 million from two top-ranked U.S. neurological health systems.
The platform now includes structured Alzheimer's disease (搜索) biomarker data with over 32,000 amyloid (搜索) and tau (搜索)-linked records, supporting trial eligibility and endpoint design.
Over 19 million patients (41% of the platform) carry both neurological and behavioral health diagnoses within the same longitudinal record, enabling comorbidity research.
Holmusk (搜索) today announced a major expansion of its NeuroBlu real-world data platform, growing to over 46 million de-identified patient lives sourced from longitudinal electronic health record (EHR) data. The 26R2 release, announced May 29, 2026, adds more than 5 million patient lives and is anchored by two new top-ranked neurological health systems — both recognized among the top U.S. News & World Report ranked Neurology hospitals — spanning the Northeastern and Southeastern United States.
"The convergence of neurological and behavioral health diagnoses within the same longitudinal record is not a feature. It is the structural foundation of the platform," said Nawal Roy, Founder and CEO of Holmusk (搜索).
Platform Scale and Geographic Expansion
The two newly integrated health systems bring complementary strengths: a top-ranked Northeastern regional health system with deep inpatient and outpatient neurology coverage, and a top-ranked Southeastern regional health system with strong neurological program depth and longitudinal patient follow-up. These additions strengthen NeuroBlu's geographic and care-setting representativeness, spanning community clinics, academic medical centers, and specialty neurology programs across the United States.
NeuroBlu's longitudinal EHR data is also linkage-ready through the DataVant ecosystem, enabling life sciences organizations to connect clinical depth to claims datasets for a broader longitudinal view of the patient journey across care settings and payer channels.
Alzheimer's Biomarker Data: A Differentiator for Trial Design
For Alzheimer's disease (搜索) research, where patient stratification by amyloid (搜索) and tau (搜索) burden is increasingly central to trial eligibility and endpoint design, NeuroBlu 26R2 provides structured biomarker laboratory data capturing amyloid and tau assessments across the patient population. The dataset includes over 4,600 occurrences of a widely used tau biomarker assay, with 32,000 total biomarker-linked records across amyloid and tau combined — creating a clinically grounded Alzheimer's disease biomarker cohort for trial support, progression modeling, and treatment response research.
The platform now includes 520,000 de-identified Alzheimer's disease (搜索) patient lives, 428,000 with mild cognitive impairment (搜索), and 2.1 million with dementia (搜索).
Validated Outcomes Measures Across Disease Areas
NeuroBlu's clinical observability extends to structured, validated outcomes measures, shifting the platform from patient counts to research-grade signal. Cognitive assessment tools include the MoCA (20,900 records), MMSE (49,800 records), and Mini-Cog (754,000 records). Motor function is captured through the Timed Up and Go assessment (121,000 records) relevant to Parkinson's disease (搜索) and ALS. Behavioral health measures include PHQ-9 (11 million records), GAD-7 (5.1 million records), and MSE (3.6 million records). Disease-specific instruments such as MIDAS for migraine (搜索) (5,600 records), the Epworth Sleepiness Scale for sleep disorders (搜索) (204,000 records), and the Numeric Rating Scale for pain (1.6 million records) are also integrated.
"When pharma teams ask if we have biomarker-confirmed AD patients with longitudinal psychiatric comorbidity and cognitive scale data — the answer is yes. When they ask about Parkinson's with motor assessments, linked sleep data and longitudinal neurological progression — yes. That level of specificity supports the evidence-generation and regulatory-oriented research workflows NeuroBlu can support," said Alex Vance, Chief Clinical Data Officer at Holmusk (搜索).
Behavioral Health Comorbidity: A Structural Foundation
NeuroBlu's whole-population ingestion model, which includes full mental health diagnostic (F-code) coverage, means neurological and behavioral health conditions are captured together within the same longitudinal record rather than assembled as separate cohorts. In the 26R2 release, over 19 million de-identified patient lives — 41% of the platform — carry both neurological and behavioral health diagnoses. Comorbidity rates across conditions such as Alzheimer's disease (搜索), Parkinson's disease (搜索), and migraine (搜索) are consistent with published literature, and psychiatric outcomes measures are available within the same patient record as neurological progression data.
Key disease-area highlights include 2.7 million migraine (搜索) patients with neurological outcomes and behavioral health comorbidity observability, 2.1 million dementia (搜索) patients with linked psychiatric outcomes and neurological progression observability, and 324,000 Parkinson's disease (搜索) patients with TUG motor assessments, psychiatric comorbidity, and linked sleep disorder data.
Advanced Neuroimaging and Future Directions
NeuroBlu 26R2 captures structured neuroimaging encounter data — including modality type, ordering context, and MRI and PET event capture — across the neurological patient population. Structured clinical interpretation and results notes are expected to be available later in 2026, at which point NeuroBlu will support linked imaging context within the longitudinal patient record for disease progression and treatment response analysis.
The platform is available now to life sciences, biopharma, and biotech organizations. Pharma teams evaluating observational study design for Alzheimer's disease (搜索) or Parkinson's progression are encouraged to request a data specification overview. Organizations with specific disease, biomarker, or outcomes data requirements are encouraged to engage early, as NeuroBlu works directly with pharma partners to assess data availability and prioritize coverage across its expanding network.